This is the raw data from CHB patients who underwent blood profile tests, including M2BPGi. All data were from the Hasan Sadikin Chronic Hepatitis B Registry. Processed Data included.
Introduction: Emerging evidence suggest that long-term nucleotide analogue (NA) therapy can be ceased in a selective group of chronic hepatitis B (CHB). This is being gradually implemented in clinical
Predicting hepatitis B surface antigen (HBsAg) clearance is important for chronic hepatitis B (CHB) patients receiving pegylated interferon-alfa (Peg-IFN) therapy. We aimed to determine the predictive
